Xanthic Biopharma Inc. (CSE:xTHC) (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) is pleased to announce two of its executives, President Gary Galitsky, and Director Dr. Gunther Hintz, made a presentation on April 25, 2018 at a cannabis conference hosted by Bangkok’s Kasetsart University, Thailand’s largest university. The theme of the conference was to educate and teach the benefits of cannabinoid-based medicine, the history of herbal use and the future state of cannabis in the world.

Attendees included the Thai Minister of Health, Director of Drug Enforcement, Justice Minister, Minister of Agriculture, Pharmacological Head of Thailand and over 200 invited attendees, comprised of Thai doctors, pharmacists and medical practitioners. Xanthic was invited to participate in this event by Dr Samnouk, of iMed Therapy Co., Ltd., one of the leading biotechnology companies in Thailand, acting as a key consultant to the Thai government. Thailand has a population of 69 million and is the second largest economy in South East Asia.


Mr. Galitsky and Dr. Hintz presented an overview of Canadian cannabis legal history and the current Canadian legal landscape. Thailand is currently evaluating the decriminalization of cannabis and is looking at Canada as a “best-in-class” source for lessons and best practices.

In addition, Mr. Galitsky and Dr. Hintz introduced the audience to the Xanthic Biopharma patent-pending technology and the benefits of the Xanthic water-soluble THC and CBD product line.

Said Mr. Galitsky: “We are honoured to have been invited to speak at this conference. It is a great opportunity to have some involvement in the evolution of legal change in Thailand and to showcase the benefits of the Xanthic water soluble products. Although it is early days, we look forward to a time when we could create partnerships in Asia to expand the Xanthic footprint.”

About Xanthic
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary patent-pending process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, accurate micro-dosing, faster onset, increased bioavailability and improved consistency versus competitive infused products.

Through its investment in Avitas CBD Water, Xanthic has access to non-cannabis derived CBD infused products that qualify for distribution outside of the Cannabis dispensary network and into mainstream retail.

Click here to connect with Xanthic Biopharma Inc. and receive an Investor’s Presentation.

Source: www.newswire.ca

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less